Introduction {#sec1-1759091419839515}
============

Frontotemporal lobar degeneration (FTLD) is the third most common dementing neurodegenerative disease in the United States, surpassed only by Alzheimer's disease (AD) and Dementia with Lewy Body Disease (DLBD; [@bibr34-1759091419839515]). The onset of FTLD-related symptoms begins between 45 and 65 years of age, and survival is just 3 to 5 years after diagnosis ([@bibr91-1759091419839515]; [@bibr8-1759091419839515]; [@bibr7-1759091419839515]). In contrast, onset of nonfamilial AD or DLBD is 65 years or older, and survival is 7 to 10 years after diagnosis ([@bibr53-1759091419839515]; [@bibr64-1759091419839515]; [@bibr54-1759091419839515]; [@bibr16-1759091419839515]). Because only 20% of FTLD cases have a clear familial or genetic link, 80% have no known etiology ([@bibr73-1759091419839515]; [@bibr7-1759091419839515]). Accompanying motor neuron disease with degeneration of brainstem motor nuclei and spinal anterior horn cells ([@bibr52-1759091419839515]; [@bibr8-1759091419839515]) accelerates the course and abbreviates survival. The neuropathology of FTLD is characterized by prominent atrophy of gray and white matter structures in the frontal lobe, insular cortex, and anterior temporal and cingulate regions ([@bibr52-1759091419839515]; [@bibr73-1759091419839515]). Atrophy is associated with neuronal loss, gliosis, and accumulations of neuronal and glial cytoplasmic inclusions that contain misfolded and mutated proteins such as the microtubule-associated protein tau, TAR DNA-binding protein 43 kDa (TDP-43), fused-in-sarcoma, or ubiquitin ([@bibr41-1759091419839515]; [@bibr47-1759091419839515]; [@bibr55-1759091419839515]). Misfolded proteins continue to be identified in FTLD, but their causal or consequential roles remain uncertain.

The neurotrophins, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT3; Sortilin) and neurotrophin-4/5 interact with high-affinity neurotrophic tropomyosine receptor kinase (Trk), which are tyrosine kinases, or low-affinity p75 neurotrophin receptor (p75NTR; [@bibr14-1759091419839515]; [@bibr95-1759091419839515]). Trk signaling promotes neuronal survival, proliferation, growth, and plasticity, whereas p75 signaling supports remodeling of axons and dendrites ([@bibr46-1759091419839515]; [@bibr38-1759091419839515]; [@bibr95-1759091419839515]). Despite evidence for neurotrophin signaling abnormalities in AD ([@bibr83-1759091419839515]), convincing data have not been generated with respect to FTLD. For example, BDNF protein expression in the frontal or temporal lobes is reduced in AD but not in FTLD ([@bibr35-1759091419839515]). Similarly, cerebrospinal fluid levels of BDNF and NGF are reduced in AD but not in FTLD ([@bibr10-1759091419839515]). While serum levels of BDNF may be lower in FTLD relative to controls ([@bibr95-1759091419839515]), the levels are not predictive of FTLD subtypes ([@bibr92-1759091419839515]).

Although most studies designed to examine roles for neurotrophin dysfunction in FTLD have been disappointingly negative, the overall number of relevant publications is small, perhaps due to difficulty in collecting well-characterized cases. Further research is justified due to the known interrelationships between neurotrophins and other molecules that can be mutated in FTLD, and clinical or experimental data showing that neurotrophin treatments can rescue some aspects of neurodegeneration ([@bibr3-1759091419839515]; [@bibr42-1759091419839515]; [@bibr1-1759091419839515]; [@bibr82-1759091419839515]). For example, progranulin, a secreted growth factor that regulates neuronal survival, synaptogenesis, and synaptic function, is normally cotransported with BDNF in axons and dendrites but mutated in FTLD ([@bibr68-1759091419839515]; [@bibr95-1759091419839515]). Therefore, BDNF's functions could be impaired by progranulin mutations. In addition, p75NTR and pro-NGF may have critical roles in the pathogenesis of FTLD-tau because upregulation of the p75NTR or increased signaling through high-affinity pro-NGF promotes tau hyperphosphorylation ([@bibr80-1759091419839515]) and activation of prodeath/antisurvival signaling ([@bibr15-1759091419839515]) via the Akt/GSK-3β pathway ([@bibr80-1759091419839515]).

An additional factor contributing to FTLD pathogenesis is oxidative stress, possibly due to mutations in TDP-43, which upregulates the unfolded protein response (UPR) leading to accumulation of ubiquitin aggregates and Golgi fragments ([@bibr88-1759091419839515]). Lipid peroxidation is another potential source of oxidative stress in neurodegenerative diseases ([@bibr81-1759091419839515]). Elevated levels of 4-hydroxynonenal (HNE) adducts in FTLD frontal cortex have been associated with increased gliosis ([@bibr60-1759091419839515]), suggesting that the astrocytic responses contribute to neurodegeneration.

On the other hand, consideration should be given to the rapidly growing literature supporting roles for insulin and insulin-like growth factor (IGF)-linked metabolic derangements, stress, and neuroinflammatory responses as mediators of AD and DLBD/Parkinson's disease (PD; [@bibr62-1759091419839515]; [@bibr11-1759091419839515]; [@bibr75-1759091419839515]; [@bibr84-1759091419839515]; [@bibr39-1759091419839515]; [@bibr22-1759091419839515]; [@bibr36-1759091419839515]; [@bibr89-1759091419839515]; [@bibr23-1759091419839515]; [@bibr25-1759091419839515]; [@bibr28-1759091419839515]). Evidence that brain metabolic abnormalities also occur in FTLD has been provided by 18F-fluorodeoxyglucose-positron emission tomography studies demonstrating frontal and temporal lobe glucose hypometabolism ([@bibr49-1759091419839515]; [@bibr71-1759091419839515]; [@bibr74-1759091419839515]), corresponding with the major regions of neurodegeneration and distinct from the patterns in AD ([@bibr48-1759091419839515]; [@bibr87-1759091419839515]; [@bibr76-1759091419839515]). Impairments in brain glucose utilization compromise cell survival, energy metabolism, mitochondrial function, myelin integrity, and synaptic plasticity ([@bibr62-1759091419839515]; [@bibr30-1759091419839515]; [@bibr26-1759091419839515]). Furthermore, many neuropathologic features in FTLD, including tau hyperphosphorylation, impaired neuronal plasticity and neurotransmitter functions, white matter atrophy, and cerebral microvascular disease could be explained by insulin- and IGF-related metabolic dysfunctions ([@bibr62-1759091419839515]; [@bibr30-1759091419839515]; [@bibr26-1759091419839515]), as demonstrated in AD and DLBD ([@bibr39-1759091419839515]). The present work assesses the presence and nature of insulin/IGF metabolic, neurotrophin, and oxidative stress-related abnormalities in human postmortem brains with FTLD.

Material and Methods {#sec2-1759091419839515}
====================

Materials {#sec3-1759091419839515}
---------

MaxiSorp Nunc 96-well plates used for enzyme-linked immunosorbent assays (ELISAs) were from Thermo Fisher Scientific (Waltham, MA, USA). Superblock-TBS and horseradish peroxidase-conjugated secondary antibodies were from Pierce Chemical Co (Rockford, IL, USA). Primary monoclonal antibodies and other immunodetection reagents were purchased from Abcam (Cambridge, MA, USA), EMD Millipore (now Millipore/Sigma, Billerica, MA, USA), Santa Cruz Biotechnology (Dallas, TX, USA), Vector Laboratories (Burlingame, CA, USA), Invitrogen (Carlsbad, CA, USA), or Life Technologies/Thermo Fisher, Inc. (Waltham, MA, USA). Fine chemicals were purchased from CalBiochem (Carlsbad, CA, USA) or Sigma-Aldrich (St. Louis, MO, USA).

Human Brain Tissue {#sec4-1759091419839515}
------------------

Postmortem frontal and temporal lobe tissue was obtained from the Taub Brain Bank at Columbia University in New York ([@bibr51-1759091419839515]; [@bibr90-1759091419839515]). Postmortem diagnoses of FTLD were made by systematic evaluation and scoring of atrophy, histopathological lesions, and immunohistochemical staining for phosphorylated tau (pTau), ubiquitin, and TDP-43 using standard criteria ([@bibr73-1759091419839515]; [@bibr21-1759091419839515]). Aged normal controls were also processed and banked using a standardized protocol ([@bibr51-1759091419839515]; [@bibr90-1759091419839515]). Permission to use deidentified postmortem human brain tissue for this research was granted by the Lifespan Hospitals institutional review board.

Direct-Binding ELISAs {#sec5-1759091419839515}
---------------------

Frontal (Brodmann's areas \[BA\]8/9 and BA24) and temporal (BA38) lobe cortical tissue homogenates were prepared in 5 volumes of lysis buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM EDTA (pH 8.0), 50 mM NaF, 0.1% Triton X-100, and protease and phosphatase inhibitors ([@bibr65-1759091419839515]). Clarified supernatants obtained by centrifuging the samples at 14,000 × g for 15 min were used in direct-binding ELISAs to measure immunoreactivity to insulin, insulin receptor (insulin R), insulin-like growth factor-1 (IGF-1), IGF-1R, insulin-like growth factor-2 (IGF-2), IGF-2R, NGF, BDNF, NT3, neurotrophin-4 (NT4), Trk, tau, pTau, transforming growth factor-beta 1 (TGF-β1), TGF- β1R, and HNE ([@bibr89-1759091419839515]). The functions of each factor are summarized in [Table 1](#table1-1759091419839515){ref-type="table"}.

###### 

Trophic and Stress Factors and Their Functions.

![](10.1177_1759091419839515-table1)

  Gene                                              Protein                                    CNS cell expression       Functions                                                                                                                                                                                                                                                                                                        Disease correlation
  ------------------------------------------------- ------------------------------------------ ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  Nerve growth factor (NGF)                         Nerve growth factor (NGF)                  Neuron                    • Produced in the cortex and hippocampus• Involved in the survival, growth, and maintenance  of sensory and sympathetic fibers (i.e., trigeminal dorsal root neurons)• Required for the maturation of cholinergic-hippocampal interaction                                                                        Decreased cholinergic activity in AD basal forebrain
  Brain-derived neurotrophic factor (BDNF)          Brain-derived neurotrophic factor (BDNF)   Neuron                    • Important in the survival and maintenance of sensory neurons,  retinal ganglion, some cholinergic neurons, spinal motor neurons,  and some dopaminergic neurons• Involved in synaptic plasticity (long-term potentiation)                                                                                      Decreased in AD, PD, HD, ALS
  Sortilin 1 (SORT1)                                Neurotrophin-3 (NT3)                       Neuron, oligodendrocyte   • Required for the normal development of oligodendrocytes• Involved in synaptic plasticity• Promotes the survival of visceral and proprioceptive  sensory neurons                                                                                                                                                
  Neurotrophin-4 (NTF4)                             Neurotrophin-4 (NT4)                       Neuron                    • Required for the survival of peripheral sensory neurons but  not sympathetic or motor neurons                                                                                                                                                                                                                  
  Neurotrophic receptor tyrosine kinase 1 (NTRK1)   Tropomyosin receptor kinase (Trk)          Neuron                    • 3 types: TrkA, TrkB, TrkC• TrkA binds NGF• TrkB binds BDNF and NT4• TrkC binds NT3• TrkA found in the cholinergic basal forebrain, striatum,  and hippocampus• TrkB and TrkC found in the cholinergic basal forebrain  but more widely distributed• Can associate with the pan neurotrophin receptor, p75NTR   Decreased TrkB in AD
                                                    4-hydroxynonenal (HNE)                                               • End product of lipid peroxidation• Increased expression during oxidative stress• Secondary signaling molecule that regulates cell death, growth,  and differentiation                                                                                                                                          
  INS                                               Insulin                                                              • Peptide hormone secreted by the beta islets cells of the pancreas  in response to a rise in blood glucose• Promotes the uptake of glucose into muscle and adipose tissue  for anabolic purposes (glycolysis and glycogen synthesis)                                                                            Insulin resistance in AD
  Insulin-like growth factor-1 (IGF-1)              Insulin-like growth factor-1 (IGF-1)                                 • Protein released by the liver in response to growth hormone  stimulation• Regulates cell growth and differentiation                                                                                                                                                                                            Increased in PD

*Note*. AD = Alzheimer's disease; ALS = amyotrophic lateral sclerosis; CNS = central nervous system; HD = Huntington's disease; PD = Parkinson's disease.

Four replicate protein samples (100 ng/50 µl) were adsorbed to the well bottoms (96-well Nunc MaxiSorp plates) by overnight incubation at 4°C and then blocked for 3 hr with Superblock (TBS). After washing, the samples were incubated with primary antibody (0.1--0.4 µg/ml) for 1 hr at 37°C. Immunoreactivity was detected with horseradish peroxidase-conjugated secondary antibody and Amplex UltraRed soluble fluorophore. Fluorescence intensity was measured (Ex 565 nm/Em 595 nm) in a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Binding specificity was determined from parallel control reactions with primary or secondary antibodies omitted. Immunoreactivity was normalized to protein content in parallel wells as determined with the NanoOrange Protein Quantification Kit. Protein quantification checks were performed to adjust for any variability in loading that may have occurred with robotic dilution of the stock sample homogenates.

Quality Assurance {#sec6-1759091419839515}
-----------------

The studies and data analyses were performed under code and repeated twice to demonstrate reproducibility of results. The animal source, nature, commercial source, and RRID number for all immunodetection reagents are provided in Supplementary Table 1. Antibody specificity was further assessed by measuring immunoreactivity in control studies in which the primary antibodies were omitted, or serially diluted to demonstrate progressive binding extinction. The election to use ELISAs rather than Western blotting to measure immunoreactivity in postmortem human tissues was based on the impracticality of simultaneously analyzing large numbers of cases on a single membrane, together with concerns about variable postmortem artefacts and disease states associated with oxidative stress leading to artificial declines in the expression of full-length proteins, despite preservation of epitopes.

Statistical Analysis {#sec7-1759091419839515}
--------------------

Data depicted in box plots reflect group medians (horizontal bar), 95% confidence interval limits (upper and lower box limits), and range (whiskers). Data were analyzed using GraphPad Prism 7 (GraphPad Inc., San Diego, CA). Intergroup comparisons were made by analysis of variance (ANOVA) with post hoc repeated measures Tukey tests and Student *t* tests. Significant *p* values are shown within the graph panels.

Results {#sec8-1759091419839515}
=======

Human Subject Groups {#sec9-1759091419839515}
--------------------

The study included 13 controls and 11 patients with FTLD. Diagnoses were confirmed in all cases by postmortem examination of the brain. Although the controls were somewhat older, the mean ages of the control and FTLD groups did not differ significantly ([Table 2](#table2-1759091419839515){ref-type="table"}). Ten of the 11 FTLD cases were male compared with 8 of 13 in the control group. Mean postmortem intervals and brain pH were similar between the FTLD and control cases. None of the FTLD cases had identified genetic mutations linked to familial forms of the disease.

###### 

Subject Characteristics.

![](10.1177_1759091419839515-table2)

  Group     No. of cases   Age           Sex         PMI (hr)    pH            Brain wt (g)
  --------- -------------- ------------- ----------- ----------- ------------- -----------------
  FTLD      11             69.6 ± 11.2   10 M, 1 F   5.3 ± 3.6   6.54 ± 0.28   1,194.3 ± 125.1
  Control   13             77.7 ± 12.1   8 M, 5 F    5.2 ± 4.6   6.66 ± 0.2    1,251.7 ± 141.3

*Note*. FTLD = frontotemporal lobar degeneration; PMI = postmortem interval.

Phosphorylated Tau {#sec10-1759091419839515}
------------------

Tau is a microtubule-associated protein that stabilizes the cytoskeleton and helps mediate dynamic cellular processes such as transport and cell division via physiological cycles of phosphorylation and dephosphorylation. However, aberrant phosphorylation of tau results in aggregation of the fibrils, ubiquitination of the protein, and activation of the UPR which triggers oxidative stress, neuronal dysfunction, and death. Elevated levels of pTau and protein ubiquitination are consistent neuropathologic features of FTLD. The ELISA studies demonstrated significantly reduced mean levels of Tau in the BA8/9 region of FTLD brains, but levels similar to control in the other two brain regions examined ([Figure 1(a)](#fig1-1759091419839515){ref-type="fig"}). The mean levels of pTau were significantly higher in the BA24 and BA38 but not BA8/9 regions of FTLD brains relative to control ([Figure 1(d)](#fig1-1759091419839515){ref-type="fig"}). Correspondingly, the mean levels of ubiquitin immunoreactivity were significantly higher in all three regions of FTLD brains relative to control ([Figure 1(f)](#fig1-1759091419839515){ref-type="fig"}).

![FTD-associated changes in markers of oxidative stress. Fresh-frozen postmortem microdissected control (*n* = 13) and FTD (*n* = 11) human brain samples from BA 8/9 (prefrontal), BA24 (anterior cingulate), and BA38 (temporal pole) were used to measure (a) Tau, (b) TGF-β1, (c) HNE, (d) pTau, (e) TGF-β1 receptor (TGF-β1R), and (f) ubiquitin by direct-binding ELISAs with results normalized to protein concentration. Levels of immunoreactivity were measured in arbitrary FLU. Box plots depict mean (horizontal bar), 95% confidence interval limits (upper and lower limits of the boxes), and range (stems). Data were analyzed by two-way ANOVA with the Tukey post hoc significance test. Significant between-group differences are indicated within the panels.\
BA = Brodmann's area; FLU = fluorescence light unit; FTD = frontotemporal lobar degeneration; HNE = 4-hydroxynonenal; pTau = phosphorylated Tau; TGF-β1 = transforming growth factor-beta 1.](10.1177_1759091419839515-fig1){#fig1-1759091419839515}

Indices of Neuroinflammation and Oxidative Stress {#sec11-1759091419839515}
-------------------------------------------------

TGF-β1 is a proinflammatory cytokine and known mediator of neuroinflammation in various neurodegenerative diseases, including AD ([@bibr61-1759091419839515]). TGF-β1 receptor is a membrane-bound serine/threonine protein kinase receptor that interacts with TGF superfamily signaling ligands, transducing growth and cytokine functions ([@bibr78-1759091419839515]). The studies demonstrated elevated mean levels of TGF-β1 in all three regions of FTLD brains, although the intergroup differences were significant only for BA8/9 and BA24 ([Figure 2(b)](#fig2-1759091419839515){ref-type="fig"}). The mean level of TGF-β1 receptor expression was modestly but significantly lower in the BA24 region of FTLD brains, whereas in BA8/9 and BA38, the expression levels were similar in the FTLD and control groups.

![FTD-associated regional alterations in neurotrophin and neurotrophin receptor immunoreactivity. Fresh-frozen postmortem microdissected control (n = 13) and FTD (n = 11) human brain samples from BA 8/9 (prefrontal), BA24 (anterior cingulate), and BA38 (temporal pole) were used to measure (a) BDNF, (b) NT3, (c) Trk, (d) NGF, and (e) NT4 by direct-binding ELISAs with results normalized to protein concentration. Levels of immunoreactivity were measured in arbitrary FLU. Box plots depict mean (horizontal bar), 95% confidence interval limits (upper and lower limits of the box), and range (stems). Data were analyzed by two-way ANOVA with the Tukey post hoc significance test. Significant between-group differences are indicated within the panels.\
BA = Brodmann's area; BDNF = brain-derived neurotrophic factor; FLU = fluorescence light unit; FTD = frontotemporal lobar degeneration; NGF = nerve growth factor; NT3 = neurotrophin-3; NT4 = neurotrophin-4; Trk = tropomyosin receptor kinase.](10.1177_1759091419839515-fig2){#fig2-1759091419839515}

Neuroinflammation and oxidative stress disrupt membrane integrity leading to lipid peroxidation. Elevated levels of HNE mark lipid peroxidation in various neurodegenerative diseases, including AD and DLBD ([@bibr89-1759091419839515]; [@bibr81-1759091419839515]). In FTLD, the mean levels of HNE immunoreactivity were significantly elevated relative to control in all three regions ([Figure 3(f)](#fig3-1759091419839515){ref-type="fig"}).

![FTD-associated regional changes in insulin/IGF trophic factors and receptors. Fresh-frozen postmortem microdissected control (n = 13) and FTD (n = 11) human brain samples from BA 8/9 (prefrontal), BA24 (anterior cingulate), and BA38 (temporal pole) were used to measure (a) insulin, (b) IGF-1, (c) IGF-2, (d) insulin receptor, (e) IGF-1 receptor, and (f) IGF-2 receptor by direct-binding ELISAs with results normalized to protein concentration. Levels of immunoreactivity were measured in arbitrary FLU. Box plots depict mean (horizontal bar), 95% confidence interval limits (upper and lower limits of the boxes), and range (stems). Data were analyzed by two-way ANOVA with the Tukey post hoc significance test. Significant between-group differences are indicated within the panels.\
BA = Brodmann's area; FLU = fluorescence light unit; FTD = frontotemporal lobar degeneration; IGF-1 = insulin-like growth factor-1; IGF-2 = insulin-like growth factor-2.](10.1177_1759091419839515-fig3){#fig3-1759091419839515}

Neurotrophins and Receptor {#sec12-1759091419839515}
--------------------------

We measured brain levels of four neurotrophins, including BDNF ([Figure 2(a)](#fig2-1759091419839515){ref-type="fig"}), NGF ([Figure 2(d)](#fig2-1759091419839515){ref-type="fig"}), NT3 ([Figure 2(b)](#fig2-1759091419839515){ref-type="fig"}), and NT4 ([Figure 2(e)](#fig2-1759091419839515){ref-type="fig"}), and the neurotrophin receptor, Trk ([Figure 2(c)](#fig2-1759091419839515){ref-type="fig"}). Neurotrophins promote growth and survival of neurons and glia, and neurotrophin receptors transmit intracellular signals that drive related responses to trophic factor stimulation. In FTLD, BDNF expression was significantly reduced in BA8/9, and NT4 was significantly reduced in BA38, whereas NGF and NT3 were significantly increased in BA38. Otherwise, the mean levels of neurotrophin expression were similar in control and FTLD samples. Trk expression was modestly but significantly elevated in BA24 of FTLD brains but similar to control in BA8/9 and BA38 ([Figure 2(e)](#fig2-1759091419839515){ref-type="fig"}).

Insulin, IGFs, and Receptors {#sec13-1759091419839515}
----------------------------

Insulin, IGF-1 and IGF-2 are regulators of cell growth and metabolism with distinct mechanisms of action. Insulin works to decrease blood glucose by increasing the cell's permeability to sugars, while IGFs regulate the cell cycle in response to trophic factor stimulation. Insulin deficiency in the brain is a feature of AD ([@bibr75-1759091419839515]; [@bibr84-1759091419839515]; [@bibr26-1759091419839515]), whereas systemic insulin deficiency is fundamental to Type 1 diabetes mellitus. In contrast, elevated levels of insulin mark states of insulin resistance, as occurs in Type 2 diabetes mellitus. In brains with FTLD, the mean levels of insulin immunoreactivity were significantly elevated in the anterior frontal (BA8/9) and cingulate (BA24) regions but not significantly changed relative to control in the temporal pole (BA38; [Figure 3(a)](#fig3-1759091419839515){ref-type="fig"}). In contrast, IGF-1 immunoreactivity was significantly reduced in BA24 of FTLD brains ([Figure 3(b)](#fig3-1759091419839515){ref-type="fig"}). Otherwise, the regional levels of IGF-1 and IGF-2 expression were similar in FTLD and control samples ([Figure 3(b) and (c)](#fig3-1759091419839515){ref-type="fig"}).

Insulin receptor expression was significantly elevated relative to control in BA24 but not BA8/9 or BA38 ([Figure 3(d)](#fig3-1759091419839515){ref-type="fig"}). The mean levels of IGF-1 receptor expression were significantly higher in BA8/9, BA24, and BA38 of FTLD relative to control samples ([Figure 3(e)](#fig3-1759091419839515){ref-type="fig"}). In contrast, IGF-2 receptor expression was modestly but significantly reduced in the BA24 and BA38 regions of FTLD brains, whereas the mean levels of IGF-2 receptor immunoreactivity were similar in BA8/9 of control and FTLD samples ([Figure 3(f)](#fig3-1759091419839515){ref-type="fig"}).

Discussion {#sec14-1759091419839515}
==========

The primary goal of this work was to determine if FTLD is associated with significant alterations in the expression of insulin, IGFs, and their corresponding receptors. The working hypothesis is that in FTLD, like AD ([@bibr75-1759091419839515]; [@bibr22-1759091419839515]; [@bibr27-1759091419839515]; [@bibr86-1759091419839515]; [@bibr25-1759091419839515]; [@bibr85-1759091419839515]) and Parkinson Disease/DLBD ([@bibr19-1759091419839515]; [@bibr36-1759091419839515]; [@bibr89-1759091419839515]; [@bibr37-1759091419839515]; [@bibr69-1759091419839515]; [@bibr4-1759091419839515]; [@bibr6-1759091419839515]), impairments in brain insulin and IGF signaling mechanisms mediate brain metabolic dysfunction, together with increased phosphorylation of Tau, neuroinflammation, oxidative stress, neuronal loss, and impaired neuronal plasticity ([@bibr30-1759091419839515]). Furthermore, all these abnormalities have been linked to insulin/IGF deficiencies or resistances in humans and experimental models with neurodegeneration ([@bibr30-1759091419839515]; [@bibr22-1759091419839515]; [@bibr24-1759091419839515]; [@bibr23-1759091419839515]; [@bibr25-1759091419839515]; [@bibr85-1759091419839515]). A potential limitation of this study is that the sample sizes were relatively small due to limited availability of well-characterized cases in the brain bank. The calculated power for alpha = .05 was .72, which is somewhat below the standard power desired of .80 and therefore could account for differences in gene expression that were graphically evident but did not reach statistical significance.

The study evaluated three brain regions targeted by FTLD including BA8/9 in the prefrontal region, BA24 in the anterior cingulate region of the frontal lobe, and BA38 within the temporal pole. BA8/9 is important for executive functions, attention, planning of motor activity, and working memory. BA24 modulates executive functions, basic instinct, motivation, and reward pathways via limbic circuitry. BA38 has functional roles in language usage, including semantic processing, speech comprehension, and naming. Therefore, the clinical features/deficits in FTLD are associated with neurodegeneration within these brain regions. Correspondingly, 18F-fluorodeoxyglucose-positron emission tomography studies revealed pronounced brain hypometabolism overlapping with atrophy of these same brain regions in FTLD ([@bibr48-1759091419839515]; [@bibr71-1759091419839515]; [@bibr74-1759091419839515]), helping to distinguish FTLD from AD and DLBD by noninvasive methods ([@bibr13-1759091419839515]).

In the present study, the brains with FTLD had significantly elevated mean levels of pTau, ubiquitin, TGF-β1, and HNE, reflecting known neuropathologic processes including aberrantly increased Tau phosphorylation, protein ubiquitination, neuroinflammation, and oxidative stress with lipid peroxidation product accumulations ([@bibr60-1759091419839515]). Although the degree of increased pTau in BA8/9 did not reach statistical significance, in that same region, the mean level of total Tau was strikingly reduced. Therefore, the relative levels of Tau phosphorylation were likely elevated and probably to greater extents in BA8/9 than in BA24 and BA38. Reduced levels of Tau expression have been reported in association with late stages of human neurodegenerative diseases ([@bibr57-1759091419839515]) and could reflect underlying severe atrophy with fiber loss and synaptic disconnection.

The higher levels of ubiquitin were anticipated because all forms of FTLD exhibit increased ubiquitin immunoreactivity ([@bibr5-1759091419839515]). Mechanistically, ubiquitin accumulation in FTLD is mediated by protein misfolding and aggregation, UPR activation of ubiquitin ligase, and attendant ubiquitin tagging of misfolded proteins such as pTau ([@bibr60-1759091419839515]; [@bibr5-1759091419839515]). Alternatively, mutations in the ubiquitin gene can lead to misfolding and accumulation of ubiquitin ([@bibr88-1759091419839515]). Because none of the cases were familial in etiology, the increased levels of ubiquitin immunoreactivity were most likely due to an accumulation of aberrantly pTau or other unknown proteins. Activation of the ubiquitin pathway leads to increased oxidative stress and neuroinflammation. Correspondingly, HNE immunoreactivity was significantly increased in all three brain regions studied. In addition, TGF-β1, which can function as a proinflammatory cytokine ([@bibr96-1759091419839515]), was upregulated in BA8/9 and BA24. Although this response provides evidence of chronic neuroinflammation in FTLD, the full spectrum of proinflammatory responses was not evaluated. Previous reports have demonstrated that neurodegeneration in FTLD is associated with activation of several other proinflammatory cytokines and chemokines ([@bibr10-1759091419839515]). However, differential regional expression/activation of specific cytokines and chemokines could account for the nonsignificant elevation of TGF-β1 in BA38, despite the presence of neuroinflammation. The fact that TGF-β1 receptor expression was not elevated in FTLD indicates that the neuroinflammatory responses to TGF-β1 as well as other ligands within the superfamily are likely mediated by cytokine activation rather than increased signal transduction via upregulated expression of the receptor.

Alterations in neurotrophin or neurotrophin receptor expression were mainly detected in BA38. The significant reduction in BDNF expression in BA8/9 overlaps with the presence of severely reduced Tau expression, together with increased ubiquitin, TGF-β1, and HNE immunoreactivities. BDNF is a neuroprotective and neurotrophic peptide essential for learning, memory, and metabolism and guards against neurobehavioral deficits, impairments in synaptic integrity, and neuronal loss ([@bibr20-1759091419839515]; [@bibr2-1759091419839515]; [@bibr58-1759091419839515]; [@bibr59-1759091419839515]). Its significant inhibition in AD correlates with neurofibrillary tangle accumulation and amyloid-beta neurotoxicity ([@bibr50-1759091419839515]). Although experimental data suggest that Tau overexpression inhibits BDNF ([@bibr77-1759091419839515]), in FTLD, this phenomenon could not account for the significant reductions in BDNF because Tau expression was not elevated. However, Tau pathology can disrupt BDNF signaling through Trk and attendant activity-dependent secretion of BDNF ([@bibr63-1759091419839515]). Although our finding of reduced BDNF in BA8/9 is discordant with results in a previous report ([@bibr35-1759091419839515]), the authors' use of Western blotting was less sensitive than the ELISAs employed in the present study.

The other three neurotrophins measured, NGF, NT3, and NT4, were significantly modulated in BA38 and not in the BA8/9 or BA24 frontal lobe regions. While NGF and NT3 expression were significantly increased, NT4, also known as neurotrophin-5 or neurotrophin-4/5, was significantly reduced. NT3, NGF, and BDNF mainly signal through TrkA, whereas NT4 signals through TrkB ([@bibr46-1759091419839515]; [@bibr15-1759091419839515]). NT3 also signals neuroprotective effects through TrkC ([@bibr70-1759091419839515]; [@bibr93-1759091419839515]). The TrkA receptor is high affinity, whereas the TrkB receptor is low affinity. Because there is no apparent overlap between NT4 and other neurotrophins and TrkA and TrkB are distinct, the reduced levels of NT4 would not likely have been compensated for by upregulation of NT3 or NGF.

Although the modest but significant increases in NT3 and NGF and attendant activation of TrkA may have compensated for the reduced levels of BDNF, the latter was observed in BA8/9 and not in BA38 where NT3, NT4, and NGF were significantly modulated. Moreover, the impact of reduced NT4 expression in FTLD is uncertain because genetic depletion of the corresponding gene produces subtle cellular abnormalities and a normal adult phenotype ([@bibr72-1759091419839515]). The increased mean level of NT3 may represent a compensatory response because previous studies demonstrated upregulation of NT3 following ischemic injury to the brain ([@bibr17-1759091419839515]). NGF, which regulates growth, proliferation, survival, and homeostasis of neurons ([@bibr1-1759091419839515]), is upregulated and probably dysregulated in AD ([@bibr42-1759091419839515]; [@bibr79-1759091419839515]; [@bibr1-1759091419839515]). Higher cortical and subcortical levels of NGF have been attributed to impaired retrograde transport to various regions with attendant deprivation of NGF-stimulated blood flow and episodic memory ([@bibr79-1759091419839515]). The significantly elevated NGF expression in BA38 may have similar consequences in FTLD.

The finding of higher mean levels of insulin expression, with or without upregulation of the insulin receptor in BA8/9 and BA24, provides new evidence for brain (frontal lobe) insulin resistance in FTLD and illustrates that brain metabolic dysfunction linked to impaired insulin signaling represents a feature shared in common with AD and DLBD ([@bibr89-1759091419839515]; [@bibr4-1759091419839515]; [@bibr26-1759091419839515]). However, the absence of altered insulin or insulin receptor expression in the FTLD temporal lobe (BA38) helps distinguish the nature of underlying metabolic dysfunctions in FTLD from AD. Because insulin signaling plays vital roles in synaptic plasticity needed for learning and memory, neuroprotection, cellular homeostasis, and energy metabolism, many of the clinical and neuropathologic frontal lobe-related abnormalities in FTLD may be attributable to insulin resistance. Furthermore, increased oxidative stress with activation of the UPR leading to neuroinflammation, aberrant tau phosphorylation, and protein ubiquitination in FTLD may also be mediated by impaired downstream signaling through PI3K-Akt pathways that regulate metabolism and enable activation of GSK-3β as occurs in AD ([@bibr33-1759091419839515]).

FTLD brains also exhibited reduced levels of IGF-1 expression in BA24, indicating IGF-1 deficiency in the anterior cingulate. Furthermore, the increased expression of IGF-1 receptor in BA8/9, BA24, and BA38 in the setting of normal IGF-1 expression reflects IGF-1 resistance in both the frontal and temporal lobes. In the brain, insulin and IGF-1 activate their own receptors but signal through highly related pathways beginning with the insulin receptor substrate docking protein that transmits signals downstream through Erk-MAPK and PI3K-Akt pathways ([@bibr30-1759091419839515]). Like insulin, IGF-1 has neurotrophic and neuroprotective effects; however, IGF-1 has a more dominant role in promoting growth ([@bibr30-1759091419839515]). In postmitotic neurons, IGF-1 stimulates growth of neuritic processes and cell fibers needed to establish and maintain connections and mediate plasticity ([@bibr30-1759091419839515]). Another key role of IGF-1 is to support myelin maintenance/integrity, survival, and function of oligodendrocytes ([@bibr24-1759091419839515]). Inhibition of IGF-1 signaling due to receptor resistance may be an important factor contributing to the severe white matter atrophy with myelin and axonal loss in FTLD.

Finally, IGF-2 expression was unchanged in FTLD, but IGF-2 receptor expression was significantly reduced in BA24 and BA38, which are both interconnected with the limbic circuit. Reduced levels of IGF-2 receptor also occur in AD, PD, and DLBD, particularly in the late stages of disease ([@bibr75-1759091419839515]; [@bibr84-1759091419839515]; [@bibr89-1759091419839515]; [@bibr26-1759091419839515]). IGF-2 receptor, like insulin and IGF-1, can activate PI3K-Akt pathways ([@bibr40-1759091419839515]; [@bibr66-1759091419839515]). Therefore, reduced expression of IGF-2 receptors could limit activation of those pathways. The IGF-2R, also called, "cation independent mannose-6-phosphate receptor," is multifunctional and binds to IGF-2 at the cell surface, and mannose-6-phosphate-tagged proteins in the trans-Golgi network ([@bibr12-1759091419839515]). IGF-2R depletion leads to motor and speech deficits and language delays. Therefore, language and motor impairments associated with FTLD, including variants with motor neuron disease, could be mediated by inhibition of IGF-2R expression ([@bibr67-1759091419839515]). Included among IGF-2R's roles are its ability to (a) sequester IGF-2 and regulate growth, particularly during development ([@bibr12-1759091419839515]); (b) activate TGF-β1 ([@bibr56-1759091419839515]); (c) be imprinted by genomic methylation and regulate expression or silencing of the maternal or paternal allele ([@bibr31-1759091419839515]); and (d) respond to stimulation by insulin or IGF-1 ([@bibr43-1759091419839515]; [@bibr32-1759091419839515]). Among these features, the effects of imprinting and late-life deimprinting may be highly relevant to neurodegeneration because methylation/demethylation and attendant alterations in gene expression and function are influenced by aging and environmental exposures ([@bibr94-1759091419839515]), that is, factors that have the potential to drive occurrences of sporadic forms of neurodegeneration, including FTLD.

Altogether, the findings herein support the hypothesis that in FTLD, like AD, PD, and DLBD, dysregulated insulin/IGF signaling in brain regions targeted by neurodegeneration mediate brain metabolic dysfunction and contribute to disease pathogenesis. One exciting aspect of these observations and conclusions is that like AD and PD, it may be possible to repurpose antidiabetes agents such as insulin and analogues of the glucagon-like peptide 1 incretin ([@bibr44-1759091419839515]; [@bibr9-1759091419839515]; [@bibr29-1759091419839515]) to treat FTLD, including its varied cytopathologies linked to metabolic dysfunction, similar to therapeutic concepts currently emerging for AD ([@bibr26-1759091419839515]; [@bibr29-1759091419839515]; [@bibr18-1759091419839515]).
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